ONCT News and Press, Oncternal Therapeutics Inc. From 04/26/22

Celularity posted revenue of $21.3M and diluted EPS of -$1.49 for FY-2021. The Company received five FDA fast track/orphan-drug destinations in FY-2021 for its lead candidates. The stock price is up 38%+ since our last coverage in September 2021, however, the company is in need of...

Clinical-stage biopharmaceutical company Oncternal Therapeutics (NASDAQ:ONCT) on Wednesday said it has deprioritized further development of its small molecule inhibitor ONCT-216 for the treatment of Ewing sarcoma, a rare and aggressive form of bone cancer. The Company said it has discontinued...

Discontinued enrollment of Phase 1/2 trial of ONCT-216 in Ewing sarcoma Resources will be primarily reallocated to our zilovertamab global registrational Phase 3 study ZILO-301, which is expected to be initiated in Q3 2022 Focus on advancing preclinical assets for hemato...

Image source: The Motley Fool. Oncternal Therapeutics, Inc. (NASDAQ: ONCT) Q4 2021 Earnings Call Mar 10, 2022 , 5:00 p.m. ET Operator Continue reading For further details see: Oncternal Therapeutics, Inc. (ONCT) Q4 2021 Earnings Call Tran...

Oncternal Therapeutics, Inc. (ONCT) Q4 2021 Earnings Conference Call March 10, 2022 05:00 PM ET Company Participants Richard Vincent - Chief Financial Officer James Breitmeyer - President & Chief Executive Officer Salim Yazji - Chief Medical Officer Conference Call Participants Hartaj Sin...

Reached consensus with the FDA on the design and major details of the global Phase 3 Study ZILO-301 to treat patients with relapsed or refractory MCL with zilovertamab plus ibrutinib, which is on track to be initiated in the second quarter of 2022 Interim Phase 1/2 results for z...

SAN DIEGO, March 07, 2022 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced that it will report fourth quarter and full year 2021 financial results after the U.S...

Oncternal Therapeutics (NASDAQ:ONCT) granted Susette Gorak, Senior Manager, Regulatory Affairs, an option to buy 12.5K common shares. The award was made on March 1, under Oncternal’s 2021 Employment Inducement Incentive Award Plan. The option has a 10-year term and an exercise pri...

Want to find the best penny stocks to buy right now? I bet you’ve got a strategy in mind. Are you hunting for chart set-ups or searching for unusual volume? Maybe you’ve got a price range in mind, like penny stocks under $1 . On the other hand, you might be looking...

Gainers: Biofrontera (NASDAQ:BFRI) +14%. Synaptogenix (NASDAQ:SNPX) +11%. IceCure Medical (NASDAQ:ICCM) +10%. Immunic (NASDAQ:IMUX) +10%. Oncternal Therapeutics (NASDAQ:ONCT) +10%. Losers: Sio Gene Therapies (NASDAQ:SIOX) -19%. Anavex Life Sciences (NASDAQ:A...